nach oben

Erschienen in:

26.04.2019 | Review Article

Gut Microbiota as a Positive Potential Therapeutic Factor in Carcinogenesis: an Overview of Microbiota-Targeted Therapy

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Cancer therapeutic methods comprising chemotherapy, radiotherapy, and surgery are so routine in cancer treatment. Remarkably, there are several personal features which affect the effectiveness of such treatments including nutrition, microbiome diversity, and physical activity which has distinct significant roles during and after therapies along with their bilateral connections. In this way, the ability of gut microbiota36 in modulating the efficacy of chemotherapeutic medications in cancer and other types of disorders is of great importance. In addition, the role of dietary, probiotic, and synthetically engineered bacteria in manipulating and optimizing the gut microbiota is of interest. Conspicuously, the correlation between the commensal microbiota and also host can regulate the physiological activities comprising the immunity system and inflammatory agents and it is scanned in the category of cancers. Bacterial species have been employed in cancer therapy; commensal microbes posse a key beneficial role in this field. Practically, the microbiota has this potential to accelerate and modulates a certain response by priming in order to release the pro-inflammatory agents. We would like to discuss these vital factors in this review as gut microbiota has the potential to be the main option for personalized cancer treatment strategies in the future. Meaning, this novel data present clinical promising feasibilities of modulating cancer therapy with using microbiota.

Tomayko E, Pillsbury L, Pray L. The human microbiome, diet, and health: workshop summary. Washington, D.C: National Academies Press; 2013. p. 196.

Yoo JY, Kim SS. Probiotics and prebiotics: present status and future perspectives on metabolic disorders. Nutrients. 2016;8:3. https://doi.org/10.3390/nu8030173.CrossRef

Douillard FP, Ribbera A, Kant R, Pietilä TE, Järvinen HM, Messing M, et al. Comparative genomic and functional analysis of 100 Lactobacillus rhamnosus strains and their comparison with strain GG. PLoS genetics. 2013;9:8. https://doi.org/10.1371/journal.pgen.1003683.CrossRef

Waldor MK, Tyson G, Borenstein E, Ochman H, Moeller A, Finlay BB, et al. Where next for microbiome research? PLoS biology. 2015;13:1. https://doi.org/10.1371/journal.pbio.1002050.CrossRef

Koppel N, Balskus EP. Exploring and understanding the biochemical diversity of the human microbiota. Cell Chem Biol. 2016;23:1. https://doi.org/10.1016/j.chembiol.2015.12.008.CrossRef

Hiergeist A, Gläsner J, Reischl U, Gessner A. Analyses of intestinal microbiota: culture versus sequencing. ILAR J. 2015;56:2. https://doi.org/10.1093/ilar/ilv017.CrossRef

Wang B, Yao M, Lv L, Ling Z, Li L. The human microbiota in health and disease. Engineering. 2017;3(1):71–82. https://doi.org/10.1016/J.ENG.2017.01.0808.CrossRef

Zhang Y-J, Li S, Gan R-Y, Zhou T, Xu D-P, Li H-B. Impacts of gut bacteria on human health and diseases. Int J Mol Sci. 2015;16(4):7493–519. https://doi.org/10.3390/ijms16047493.CrossRefPubMedPubMedCentral

Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ. Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis. 2015;26(1):26191. https://doi.org/10.3402/mehd.v26.26191.CrossRefPubMed

10.

Costello EK, Stagaman K, Dethlefsen L, Bohannan BJ, Relman DA. The application of ecological theory toward an understanding of the human microbiome. Science. 2012;336(6086):1255–62. https://doi.org/10.1126/science.1224203.CrossRefPubMedPubMedCentral

11.

Schmitz S, Suchodolski J. Understanding the canine intestinal microbiota and its modification by pro-, pre-and synbiotics–what is the evidence? J Vet Med Sci. 2016;2(2):71–94. https://doi.org/10.1002/vms3.17.CrossRef

12.

Becker S. A historic and scientific review of breast cancer: the next global healthcare challenge. Int J Gynaecol Obstet. 2015;131(Supp1, 1). https://doi.org/10.1016/j.ijgo.2015.03.015.

13.

Tamaki K, Tamaki N, Kamada Y, Uehara K, Zaha H, Onomura M, et al. The challenge to reduce breast cancer mortality in Okinawa: consensus of the first Okinawa breast oncology meeting. Jpn J Clin Oncol. 2013;43(2):208–13. https://doi.org/10.1093/jjco/hys217.CrossRefPubMed

14.

Bodai BI, Tuso P. Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations. Perm J. 2015;19(2):48. https://doi.org/10.7812/TPP/14-241.CrossRefPubMedPubMedCentral

15.

Goroll AH, Mulley AG. Primary care medicine: office evaluation and management of the adult patient. Philadelphia: Lippincott Williams & Wilkins; 2012. 1613 P.

16.

Collins AS. Preventing health care–associated infections. In: Hughes RG, editor. Patient safety and quality: an evidence-based handbook for nurses. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008. Chapter 41. Available from: https://www.ncbi.nlm.nih.gov/books/NBK2683/.

17.

Wells N, Pasero C, McCaffery M. Improving the quality of care through pain assessment and management. In: Hughes RG, editor. Patient safety and quality: an evidence-based handbook for nurses. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008. Chapter 17. Available from: https://www.ncbi.nlm.nih.gov/books/NBK2658/.

18.

Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13(11):800–12. https://doi.org/10.1038/nrc3610.CrossRefPubMedPubMedCentral

19.

Abedin-Do A, Taherian-Esfahani Z, Ghafouri-Fard S, Ghafouri-Fard S, Motevaseli E. Immunomodulatory effects of Lactobacillus strains: emphasis on their effects on cancer cells. Immunotherapy. 2015;7(12):1307–29. https://doi.org/10.2217/imt.15.92.CrossRefPubMed

20.

Nouri Z, Karami F, Neyazi N, Modarressi MH, Karimi R, Khorramizadeh MR, et al. Dual anti-metastatic and anti-proliferative activity assessment of two probiotics on HeLa and HT-29 cell lines. Cell J. 2016;18(2):127.PubMedPubMedCentral

21.

Gibson RJ, Stringer AM. Chemotherapy-induced diarrhoea. Curr Opin Support Palliat Care. 2009;3(1):31–5. https://doi.org/10.1097/SPC.0b013e32832531bb.CrossRefPubMed

22.

Rudolph A, Chang-Claude J, Schmidt MK. Gene–environment interaction and risk of breast cancer. Br J Cancer. 2016;114(2):125–33. https://doi.org/10.1038/bjc.2015.439.CrossRefPubMedPubMedCentral

23.

Woolcott CG, Shvetsov YB, Stanczyk FZ, Wilkens LR, White KK, Caberto C, et al. Plasma sex hormone concentrations and breast cancer risk in an ethnically diverse population of postmenopausal women: the multiethnic cohort study. Endocr Relat Cancer. 2010;17(1):125–34. https://doi.org/10.1677/ERC-09-0211.CrossRefPubMedPubMedCentral

24.

Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, Schünemann HJ, et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2: 16α-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology. 2000;11(6):635–40.CrossRefPubMed

25.

Lombardi P, Goldin B, Boutin E, Gorbach SL. Metabolism of androgens and estrogens by human fecal microorganisms. J Steroid Biochem. 1978;9(8):795–801.CrossRefPubMed

26.

Narikiyo M, Tanabe C, Yamada Y, Igaki H, Tachimori Y, Kato H, et al. Frequent and preferential infection of Treponema denticola, Streptococcus mitis, and Streptococcus anginosus in esophageal cancers. Cancer Sci. 2004;95(7):569–74. https://doi.org/10.1111/j.1349-7006.2004.tb02488.x.CrossRefPubMed

27.

Yang L, Lu X, Nossa CW, Francois F, Peek RM, Pei Z. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology. 2009;137(2):588–97. https://doi.org/10.1053/j.gastro.2009.04.046.CrossRefPubMed

28.

Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546–58. https://doi.org/10.1126/science.1235122.CrossRefPubMedPubMedCentral

29.

Schetter AJ, Heegaard NH, Harris CC. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis. 2009;31(1):37–49. https://doi.org/10.1093/carcin/bgp272.CrossRefPubMedPubMedCentral

30.

Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity. 2013;39(1):11–26. https://doi.org/10.1016/j.immuni.2013.07.008.CrossRefPubMed

31.

Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu Rev Immunol. 2012;30:677–706. https://doi.org/10.1146/annurev-immunol-020711-075008.CrossRefPubMed

32.

Bronte V, Chappell DB, Apolloni E, Cabrelle A, Wang M, Hwu P, et al. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. The Journal of Immunology. 1999;162(10):5728–37.PubMed

33.

Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–99. https://doi.org/10.1016/j.cell.2010.01.025.CrossRefPubMedPubMedCentral

34.

Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zamboni P, et al. Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+ T cells. Blood. 2000;96(12):3838–46.CrossRefPubMed

35.

Cecchini MJ, Yu E, Potvin K, D'souza D, Lock M. Concurrent or sequential hormonal and radiation therapy in breast cancer: a literature review. Cureus. 2015;7(10). https://doi.org/10.7759/cureus.364.

36.

Nounou MI, ElAmrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H. Breast cancer: conventional diagnosis and treatment modalities and recent patents and technologies. Breast Cancer: Basic Clin Res. 2015;9(Suppl (2)):17–34. https://doi.org/10.4137/BCBCR.S29420.CrossRef

37.

Blumen H, Fitch K, Polkus V. Comparison of treatment costs for breast cancer, by tumor stage and type of service. Am Health Drug Benefits. 2016;9(1):23.PubMedPubMedCentral

38.

Abdulkareem I, Zurmi I. Review of hormonal treatment of breast cancer. Niger J Clin Pract. 2012;15(1):9–14. https://doi.org/10.4103/1119-3077.94088.CrossRefPubMed

39.

Ho M-L, Chen P-N, Chu S-C, Kuo D-Y, Kuo W-H, Chen J-Y, et al. Peonidin 3-glucoside inhibits lung cancer metastasis by downregulation of proteinases activities and MAPK pathway. Nutr Cancer. 2010;62(4):505–16. https://doi.org/10.1080/01635580903441261.CrossRefPubMed

40.

Lee S-J, Hong S, Yoo S-H, Kim G-W. Cyanidin-3-O-sambubioside from Acanthopanax sessiliflorus fruit inhibits metastasis by downregulating MMP-9 in breast cancer cells MDA-MB-231. Planta Med. 2013;79(17):1636–40. https://doi.org/10.1055/s-0033-1350954.CrossRefPubMed

41.

Yoshimaru T, Komatsu M, Tashiro E, Imoto M, Osada H, Miyoshi Y, et al. Xanthohumol suppresses oestrogen-signalling in breast cancer through the inhibition of BIG3-PHB2 interactions. Sci Rep. 2014;4:7355. https://doi.org/10.1038/srep07355.CrossRefPubMedPubMedCentral

42.

Lewandowska U, Szewczyk K, Owczarek K, Hrabec Z, Podsędek A, Sosnowska D, et al. Procyanidins from evening primrose (Oenothera paradoxa) defatted seeds inhibit invasiveness of breast cancer cells and modulate the expression of selected genes involved in angiogenesis, metastasis, and apoptosis. Nutr Cancer. 2013;65(8):1219–31. https://doi.org/10.1080/01635581.2013.830314.CrossRefPubMed

43.

Zhou Y, Zheng J, Li Y, Xu D-P, Li S, Chen Y-M, et al. Natural polyphenols for prevention and treatment of cancer. Nutrients. 2016;8(8):515. https://doi.org/10.3390/nu8080515.CrossRefPubMedCentral

44.

Paci A, Veal G, Bardin C, Levêque D, Widmer N, Beijnen J, et al. Review of therapeutic drug monitoring of anticancer drugs part 1–cytotoxics. Eur J Cancer. 2014;50(12):2010–9. https://doi.org/10.1016/j.ejca.2014.04.014.CrossRefPubMed

45.

Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol. 2000;18(13):2505–14.CrossRefPubMed

46.

Ausanee Wanchai MSNR. Complementary and alternative medicine use among women with breast cancer: a systematic review. Clin J Oncol Nurs. 2010;14(4):E45. https://doi.org/10.1188/10.CJON.E45-E55.CrossRefPubMed

47.

Astin J, Reilly C, Perkins C, Child W. Breast cancer patients’ perspectives on and use of complementary and alternative medicine: a study by the Susan G. Komen Breast Cancer Foundation. J Soc Integr Oncol. 2006;4(4):157–69.CrossRefPubMed

48.

Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506. https://doi.org/10.1038/nrgastro.2014.66.CrossRefPubMed

49.

Simon O, Vahjen W, Scharek L. Micro-organisms as feed additives-probiotics. Advances in pork Production. 2005;16:161–7.

50.

European Food Safety Authority (EFSA). Scientific opinion on the update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA (2017 update). EFSA J. 2017;15:1–177. https://doi.org/10.2903/j.efsa.2017.4664.CrossRef

51.

Markowiak P, Śliżewska K. Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients. 2017;9(9):1021. https://doi.org/10.3390/nu9091021.CrossRefPubMedCentral

52.

Pandey KR, Naik SR, Vakil BV. Probiotics, prebiotics and synbiotics-a review. J Food Sci Technol. 2015;52(12):7577–87. https://doi.org/10.1007/s13197-015-1921-1.CrossRefPubMedPubMedCentral

53.

Pineiro M, Asp N-G, Reid G, Macfarlane S, Morelli L, Brunser O, et al. FAO technical meeting on prebiotics. J Clin Gastroenterol. 2008;42:S156–S9. https://doi.org/10.1097/MCG.0b013e31817f184e.CrossRefPubMed

54.

Blaser MJ. Probiotics and prebiotics: where are we going? Emerg Infect Dis. 2003;9(5):610. https://doi.org/10.3201/eid0905.030134.CrossRefPubMedCentral

55.

Holscher HD. Dietary fiber and prebiotics and the gastrointestinal microbiota. Gut Microbes. 2017;8(2):172–84. https://doi.org/10.1080/19490976.2017.1290756.CrossRefPubMedPubMedCentral

56.

Jakubczyk E, Kosikowska M. Nowa generacja mlecznych produktow fermentowanych z udzialem probiotykow i prebiotykow, produkty synbiotyczne. Prz. Mlecz. 2000;12:397–400.

57.

Cencic A, Chingwaru W. The role of functional foods, nutraceuticals, and food supplements in intestinal health. Nutrients. 2010;2(6):611–25. https://doi.org/10.3390/nu2060611.CrossRefPubMedPubMedCentral

58.

Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science. 2010;330(6005):831–5. https://doi.org/10.1126/science.1191175.CrossRefPubMedPubMedCentral

59.

Lam W, Bussom S, Guan F, Jiang Z, Zhang W, Gullen EA, et al. The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci Transl Med. 2010;2(45):45–59. https://doi.org/10.1126/scitranslmed.3001270.CrossRef

60.

Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342(6161):967–70. https://doi.org/10.1126/science.1240527.CrossRefPubMedPubMedCentral

61.

Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342(6161):971–6. https://doi.org/10.1126/science.1240537.CrossRefPubMedPubMedCentral

62.

Zitvogel L, Galluzzi L, Viaud S, Vétizou M, Daillère R, Merad M, et al. Cancer and the gut microbiota: an unexpected link. Sci Transl Med. 2015;7(271):271ps1-ps1. https://doi.org/10.1126/scitranslmed.3010473.CrossRef

63.

Schachtsiek M, Hammes WP, Hertel C. Characterization of Lactobacillus coryniformis DSM 20001T surface protein Cpf mediating coaggregation with and aggregation among pathogens. Appl Environ Microbiol. 2004;70(12):7078–85. https://doi.org/10.1128/AEM.70.12.7078-7085.2004.CrossRefPubMedPubMedCentral

64.

Oelschlaeger TA. Mechanisms of probiotic actions–a review. Int J Med Microbiol. 2010;300(1):57–62. https://doi.org/10.1016/j.ijmm.2009.08.005.CrossRefPubMed

65.

Cremonini F, Di Caro S, Nista EC, Bartolozzi F, Capelli G, Gasbarrini G, et al. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2002;16(8):1461–7. https://doi.org/10.1046/j.1365-2036.2002.01318.x.CrossRefPubMed

66.

Johnston BC, Supina AL, Vohra S. Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. CMAJ. 2006;175(4):377–83. https://doi.org/10.1503/cmaj.051603.CrossRefPubMedPubMedCentral

67.

Vandenbergh PA. Lactic acid bacteria, their metabolic products and interference with microbial growth. FEMS Microbiol Rev. 1993;12(1-3):221–37. https://doi.org/10.1111/j.1574-6976.1993.tb00020.x.CrossRef

68.

Guillot J. Probiotic feed additives. J Vet Pharmacol Ther. 2003;26:52–5.

69.

Isolauri E, Sütas Y, Kankaanpää P, Arvilommi H, Salminen S. Probiotics: effects on immunity. Am J Clin Nutr. 2001;73(Suppl(2):444s–50s. https://doi.org/10.1093/ajcn/73.2.444s.CrossRefPubMed

70.

Brandão RL, Castro IM, Bambirra EA, Amaral SC, Fietto LG, Tropia MJM, et al. Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae. Appl Environ Microbiol. 1998;64(2):564–8.CrossRefPubMedPubMedCentral

71.

Motevaseli E, Shirzad M, Akrami SM, Mousavi A-S, Mirsalehian A, Modarressi MH. Normal and tumour cervical cells respond differently to vaginal lactobacilli, independent of pH and lactate. J Med Microbiol. 2013;62(7):1065–72. https://doi.org/10.1099/jmm.0.057521-0.CrossRefPubMed

72.

Modarressi RE-V, Daneshvar M, Beigom M, Mobasheri EM. Lactobacillus acidophilus and Lactobacillus crispatus culture supernatants downregulate expression of cancer-testis genes in the MDA-MB-231 cell line. Asian Pac J Cancer Prev. 2014;15(10):4255–9. https://doi.org/10.7314/APJCP.2014.15.10.4255.CrossRefPubMed

73.

Matsuzaki T, Yokokura T, Mutai M. The role of lymph node cells in the inhibition of metastasis by subcutaneous injection of Lactobacillus casei in mice. Med Microbiol Immunol. 1988;177(5):245–53.CrossRefPubMed

74.

Ciernikova S, Mego M, Hainova K, Adamcikova Z, Stevurkova V, Zajac V. Modification of microflora imbalance: future directions for prevention and treatment of colorectal cancer. Neoplasma. 2015;62(3):345–52. https://doi.org/10.4149/neo_2015_042.CrossRefPubMed

75.

Hempel S, Newberry SJ, Maher AR, Wang Z, Miles JN, Shanman R, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. Jama. 2012;307(18):1959–69. https://doi.org/10.1001/jama.2012.3507.CrossRefPubMed

76.

Sharma V, Garg S, Aggarwal S. Probiotics and liver disease. Perm J. 2013;17(4):62. https://doi.org/10.7812/TPP/12-144.CrossRefPubMedPubMedCentral

77.

He T, Priebe M, Zhong Y, Huang C, Harmsen H, Raangs G, et al. Effects of yogurt and bifidobacteria supplementation on the colonic microbiota in lactose-intolerant subjects. J Appl Microbiol. 2008;104(2):595–604. https://doi.org/10.1111/j.1365-2672.2007.03579.x.CrossRefPubMed

78.

Kajander K, Myllyluoma E, RAJILIĆ-STOJANOVIĆ M, Kyrönpalo S, Rasmussen M, Järvenpää S, et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther. 2008;27(1):48–57. https://doi.org/10.1111/j.1365-2036.2007.03542.x.CrossRefPubMed

79.

Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119(2):305–9. https://doi.org/10.1053/gast.2000.9370.CrossRefPubMed

80.

Norman HA, Butrum RR, Feldman E, Heber D, Nixon D, Picciano MF, et al. The role of dietary supplements during cancer therapy. J Nutr. 2003;133(11):3794S–9S. https://doi.org/10.1093/jn/133.11.3794S.CrossRefPubMed

81.

AFRC RF. Probiotics in man and animals. J Appl Microbiol. 1989;66(5):365–78. https://doi.org/10.1111/j.1365-2672.1989.tb05105.x.CrossRef

82.

Hotel ACP, Cordoba A. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Prevention. 2001;5(1). https://doi.org/10.1016/j.foodchem.2019.03.068.

83.

Davila M, Bresalier RS. Gastrointestinal complications of oncologic therapy. Nat Clin Pract Gastroenterol Hepatol. 2008;5(12):682–96. https://doi.org/10.1038/ncpgasthep1277.CrossRefPubMed

84.

Vincenzi B, Schiavon G, Pantano F, Santini D, Tonini G. Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer. Nat Clin Pract Oncol. 2008;5(8):455–65. https://doi.org/10.1038/ncponc1137.CrossRefPubMed

85.

Salminen E, Elomaa I, Minkkinen J, Vapaatalo H, Salminen S. Preservation of intestinal integrity during radiotherapy using live Lactobacillus acidophilus cultures. Clin Radiol. 1988;39(4):435–7. https://doi.org/10.1016/S0009-9260(88)80296-4.CrossRefPubMed

86.

Urbancsek H, Kazar T, Mezes I, Neumann K. Results of a double-blind, randomized study to evaluate the efficacy and safety of Antibiophilus® in patients with radiation-induced diarrhoea. Eur J Gastroenterol Hepatol. 2001;13(4):391–6.CrossRefPubMed

87.

Delia P, Sansotta G, Donato V, Messina G, Frosina P, Pergolizzi S, et al. Prevention of radiation-induced diarrhea with the use of VSL# 3, a new high-potency probiotic preparation. Am J Gastroenterol. 2002;97(8):2150. https://doi.org/10.1111/j.1572-0241.2002.05946.x.CrossRefPubMed

88.

Tao Y, Drabik KA, Waypa TS, Musch MW, Alverdy JC, Schneewind O, et al. Soluble factors from Lactobacillus GG activate MAPKs and induce cytoprotective heat shock proteins in intestinal epithelial cells. Am J Physiol Cell Physiol. 2006;290(4):C1018–C30. https://doi.org/10.1152/ajpcell.00131.2005.CrossRefPubMed

89.

Yan F, Cao H, Cover TL, Whitehead R, Washington MK, Polk DB. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology. 2007;132(2):562–75. https://doi.org/10.1053/j.gastro.2006.11.022.CrossRefPubMed

90.

Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One. 2012;7(4):e34938. https://doi.org/10.1371/journal.pone.0034938.CrossRefPubMedPubMedCentral

91.

Gibson RJ, Keefe DM, Lalla RV, Bateman E, Blijlevens N, Fijlstra M, et al. Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer. 2013;21(1):313–26. https://doi.org/10.1007/s00520-012-1644-z.CrossRefPubMed

92.

Delia P, Sansotta G, Donato V, Frosina P, Messina G, De Renzis C, et al. Use of probiotics for prevention of radiation-induced diarrhea. World J Gastroenterol. 2007;13(6):912. https://doi.org/10.3748/wjg.v13.i6.912.CrossRefPubMedPubMedCentral

93.

Bellm L, Epstein J, Rose-Ped A, Martin P, Fuchs H. Patient reports of complications of bone marrow transplantation. Support Care Cancer. 2000;8(1):33–9.CrossRefPubMed

94.

Blijlevens N, Donnelly J, De Pauw B. Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant. 2000;25(12):1269. https://doi.org/10.1038/sj.bmt.1702447.CrossRefPubMedPubMedCentral

95.

Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001;19(8):2201–5. https://doi.org/10.1200/JCO.2001.19.8.2201.CrossRefPubMed

96.

Packey CD, Ciorba MA. Microbial influences on the small intestinal response to radiation injury. Curr Opin Gastroenterol. 2010;26(2):88. https://doi.org/10.1097/MOG.0b013e3283361927.CrossRefPubMedPubMedCentral

97.

Touchefeu Y, Montassier E, Nieman K, Gastinne T, Potel G, Bruley d, et al. Systematic review: the role of the gut microbiota in chemotherapy-or radiation-induced gastrointestinal mucositis–current evidence and potential clinical applications. Aliment Pharmacol Ther. 2014;40(5):409–21. https://doi.org/10.1111/apt.12878.CrossRefPubMed

98.

Ciorba MA, Stenson WF. Probiotic therapy in radiation-induced intestinal injury and repair. Ann N Y Acad Sci. 2009;1165(1):190–4. https://doi.org/10.1111/j.1749-6632.2009.04029.x.CrossRefPubMedPubMedCentral

99.

Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120(10):1453–61. https://doi.org/10.1002/cncr.28592.CrossRefPubMed

100.

Tijerina AJ. The biochemical basis of metabolism in cancer cachexia. Dimens Crit Care Nurs. 2004;23(6):237–43.CrossRefPubMed

101.

Aoyagi T, Terracina KP, Raza A, Matsubara H, Takabe K. Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol. 2015;7(4):17. https://doi.org/10.4251/wjgo.v7.i4.17.CrossRefPubMedPubMedCentral

102.

Consul N, Guo X, Coker C, Lopez-Pintado S, Hibshoosh H, Zhao B, et al. Monitoring metastasis and cachexia in a patient with breast cancer: a case study. Clin Med Insights Oncol. 2016;10:83–94. https://doi.org/10.4137/CMO.S40479.CrossRefPubMedPubMedCentral

103.

Delzenne NM, Cani PD, Everard A, Neyrinck AM, Bindels LB. Gut microorganisms as promising targets for the management of type 2 diabetes. Diabetologia. 2015;58(10):2206–17. https://doi.org/10.1007/s00125-015-3712-7.CrossRefPubMed

104.

Bindels LB, Neyrinck AM, Claus SP, Le Roy CI, Grangette C, Pot B, et al. Synbiotic approach restores intestinal homeostasis and prolongs survival in leukaemic mice with cachexia. ISME J. 2016;10(6):1456–70. https://doi.org/10.1038/ismej.2015.209.CrossRefPubMed

105.

Klein GL, Petschow BW, Shaw AL, Weaver E. Gut barrier dysfunction and microbial translocation in cancer cachexia: a new therapeutic target. Curr Opin Support Palliat Care. 2013;7(4):361. https://doi.org/10.1097/SPC.0000000000000017.CrossRefPubMedPubMedCentral

106.

Akbulut G. New perspective for nutritional support of cancer patients: enteral/parenteral nutrition. Exp Ther Med. 2011;2(4):675–84. https://doi.org/10.3892/etm.2011.247.CrossRefPubMedPubMedCentral

107.

Rangaraj G, Granwehr BP, Jiang Y, Hachem R, Raad I. Perils of quinolone exposure in cancer patients. Cancer. 2010;116(4):967–73. https://doi.org/10.1002/cncr.24812.CrossRefPubMed

108.

Satlin MJ, Cohen N, Ma KC, Gedrimaite Z, Soave R, Askin G, et al. Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies. J Infect. 2016;73(4):336–45. https://doi.org/10.1016/j.jinf.2016.07.002.CrossRefPubMedPubMedCentral

109.

Hand TW. The role of the microbiota in shaping infectious immunity. Trends Immunol. 2016;37(10):647–58. https://doi.org/10.1016/j.it.2016.08.007.CrossRefPubMedPubMedCentral

110.

Pamer EG. Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science. 2016;352(6285):535–8. https://doi.org/10.1126/science.aad9382.CrossRefPubMedPubMedCentral

111.

Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol. 2013;13(11):790–801. https://doi.org/10.1038/nri3535.CrossRefPubMedPubMedCentral

112.

Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012;336(6086):1268–73. https://doi.org/10.1126/science.1223490.CrossRefPubMedPubMedCentral

113.

van Vliet MJ, Harmsen HJ, de Bont ES, Tissing WJ. The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog. 2010;6(5):e1000879. https://doi.org/10.1371/journal.ppat.1000879.CrossRefPubMedPubMedCentral

114.

Ivanov II, Honda K. Intestinal commensal microbes as immune modulators. Cell Host Microbe. 2012;12(4):496–508. https://doi.org/10.1016/j.chom.2012.09.009.CrossRefPubMedPubMedCentral

115.

Furusawa Y, Obata Y, Hase K. Commensal microbiota regulates T cell fate decision in the gut. Semin Immunopathol. 2015;37(1):17–25. https://doi.org/10.1007/s00281-014-0455-3.CrossRefPubMed

116.

Wrzosek L, Miquel S, Noordine M-L, Bouet S, Chevalier-Curt MJ, Robert V, et al. Bacteroides thetaiotaomicron and Faecalibacterium prausnitziiinfluence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent. BMC Biol. 2013;11(1):61. https://doi.org/10.1186/1741-7007-11-61.CrossRefPubMedPubMedCentral

117.

Frick JS, Schenk K, Quitadamo M, Kahl F, Köberle M, Bohn E, et al. Lactobacillus fermentum attenuates the proinflammatory effect of Yersinia enterocolitica on human epithelial cells. Inflamm Bowel Dis. 2007;13(1):83–90. https://doi.org/10.1002/ibd.20009.CrossRefPubMed

118.

O’hara AM, O’regan P, Fanning A, O’mahony C, MacSharry J, Lyons A, et al. Functional modulation of human intestinal epithelial cell responses by Bifidobacterium infantis and Lactobacillus salivarius. Immunology. 2006;118(2):202–15. https://doi.org/10.1111/j.1365-2567.2006.02358.x.CrossRefPubMedPubMedCentral

119.

Ewaschuk JB, Diaz H, Meddings L, Diederichs B, Dmytrash A, Backer J, et al. Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function. Am J Physiol Gastrointest Liver Physiol. 2008;295(5):G1025–G34. https://doi.org/10.1152/ajpgi.90227.2008.CrossRefPubMed

120.

Guo S, Gillingham T, Guo Y, Meng D, Zhu W, Walker WA, et al. Secretions of Bifidobacterium infantis and Lactobacillus acidophilus protect intestinal epithelial barrier function. J Pediatr Gastroenterol Nutr. 2017;64(3):404–12. https://doi.org/10.1097/MPG.0000000000001310.CrossRefPubMed

121.

Laval L, Martin R, Natividad J, Chain F, Miquel S, De Maredsous CD, et al. Lactobacillus rhamnosus CNCM I-3690 and the commensal bacterium Faecalibacterium prausnitzii A2-165 exhibit similar protective effects to induced barrier hyper-permeability in mice. Gut microbes. 2015;6(1):1–9. https://doi.org/10.4161/19490976.2014.990784.CrossRefPubMedPubMedCentral

122.

Martín R, Miquel S, Chain F, Natividad JM, Jury J, Lu J, et al. Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model. BMC Microbiol. 2015;15(1):67. https://doi.org/10.1186/s12866-015-0400-1.CrossRefPubMedPubMedCentral

123.

Wang H, Jatmiko YD, Bastian SE, Mashtoub S, Howarth GS. Effects of supernatants from Escherichia coli Nissle 1917 and Faecalibacterium prausnitzii on intestinal epithelial cells and a rat model of 5-fluorouracil-induced mucositis. Nutr Cancer. 2017;69(2):307–18. https://doi.org/10.1080/01635581.2017.1263747.CrossRefPubMed

124.

Hopko DR, Armento ME, Robertson S, Ryba MM, Carvalho JP, Colman LK, et al. Brief behavioral activation and problem-solving therapy for depressed breast cancer patients: randomized trial. J Consult Clin Psychol. 2011;79(6):834. https://doi.org/10.1037/a0025450.CrossRefPubMed

125.

Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999;85(3):640–50.CrossRefPubMed

126.

Kissane DW, Grabsch B, Love A, Clarke DM, Bloch S, Smith GC. Psychiatric disorder in women with early stage and advanced breast cancer: a comparative analysis. Aust N Z J Psychiatry. 2004;38(5):320–6. https://doi.org/10.1080/j.1440-1614.2004.01358.x.CrossRefPubMed

127.

Van Dam FS, Boogerd W, Schagen SB, Muller MJ, Droogleever Fortuyn ME, Ev W, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998;90(3):210–8.CrossRefPubMed

128.

Olin JJ. Cognitive function after systemic therapy for breast cancer. Oncology (Williston Park). 2001;15(5):613–8 discussion 8, 21-4.

129.

Pasacreta JV. Depressive phenomena, physical symptom distress, and functional status among women with breast cancer. Nurs Res. 1997;46(4):214–21.CrossRefPubMed

130.

Fann JR, Thomas-Rich AM, Katon WJ, Cowley D, Pepping M, McGregor BA, et al. Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry. 2008;30(2):112–26. https://doi.org/10.1016/j.genhosppsych.2007.10.008.CrossRefPubMed

131.

Montgomery GH, Bovbjerg DH. Presurgery distress and specific response expectancies predict postsurgery outcomes in surgery patients confronting breast cancer. Health Psychol. 2004;23(4):381. https://doi.org/10.1037/0278-6133.23.4.381.CrossRefPubMed

132.

Bower JE. Cancer-related fatigue: links with inflammation in cancer patients and survivors. Brain Behav Immun. 2007;21(7):863–71. https://doi.org/10.1016/j.bbi.2007.03.013.CrossRefPubMedPubMedCentral

133.

Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin TR. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol. 2000;18(4):743. https://doi.org/10.1200/JCO.2000.18.4.743.CrossRefPubMed

134.

Bower JE, Ganz PA, Desmond KA, Bernaards C, Rowland JH, Meyerowitz BE, et al. Fatigue in long-term breast carcinoma survivors. Cancer. 2006;106(4):751–8. https://doi.org/10.1002/cncr.21671.CrossRefPubMed

135.

Bardwell WA, Ancoli-Israel S. Breast cancer and fatigue. Sleep Med Clin. 2008;3(1):61–71. https://doi.org/10.1016/j.jsmc.2007.10.011.CrossRefPubMedPubMedCentral

136.

Ganz PA, Bower JE. Cancer related fatigue: a focus on breast cancer and Hodgkin’s disease survivors. Acta Oncol. 2007;46(4):474–9. https://doi.org/10.1080/02841860701367845.CrossRefPubMed

137.

Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med. 2002;64(4):604–11.CrossRefPubMed

138.

Berger AM, Higginbotham P. Correlates of fatigue during and following adjuvant breast cancer chemotherapy: a pilot study. Oncol Nurs Forum. 2000;27(9):1443–8.PubMed

139.

Evrensel A, Ceylan ME. The gut-brain axis: the missing link in depression. Clin Psychopharmacol Neurosci. 2015;13(3):239. https://doi.org/10.9758/cpn.2015.13.3.239.CrossRefPubMedPubMedCentral

140.

Huang R, Wang K, Hu J. Effect of probiotics on depression: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 2016;8(8):483. https://doi.org/10.3390/nu8080483.CrossRefPubMedCentral

141.

Alexander JL, Wilson ID, Teare J, Marchesi JR, Nicholson JK, Kinross JM. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol. 2017;14(6):356–65. https://doi.org/10.1038/nrgastro.2017.20.CrossRefPubMed

142.

Samadani AA, Norollahi SE, Rashidy-Pour A, Mansour-Ghanaei F, Nemati S, Joukar F, et al. Cancer signaling pathways with a therapeutic approach; an overview in epigenetic regulation of cancer stem cells. Biomed Pharmacother. 2018;108:590–9.CrossRefPubMed

143.

Samadani AA, Mansour-Ghanaei F, Noroollahi SE. Fluctuations of epigenetic regulation in human gastric adenocarcinoma: how does it affect? Biomed Pharmacother. January 2019;109:144–56.CrossRefPubMed

144.

Akbar Samadani A, Nikbakhsh N, Pilehchian M, Fattahi S, Akhavan-Niaki H. Epigenetic changes of CDX2 in gastric adenocarcinoma. J Cell Commun Signal. 2016. 10(4):267-272.

145.

Langroudi MP, Samadani AA, Fattahi S, Nikbakhsh N, Langroudi RP, Akhavan-Niaki H. Methylation mediated repression of FAT4 contributes to gastric adenocarcinoma development. J Cell Commun Signal. -016-0355-5. 2016. https://doi.org/10.1007/s12079-016-0355-5.

146.

Norollahi SE, Alipour M, Rashidy-Pour A, Samadani AA. Laleh Vahedi Larijani, Regulatory fluctuation of WNT16 gene expression is associated with human gastric adenocarcinoma. J Gastrointest Cancer. 2107:1–6. https://doi.org/10.1007/s12029-017-0022-y.

147.

Kosari-Monfared M, Nikbakhsh N, Fattahi S, Ghadami E, Ranaei M. Hassan Taheri,Fatemeh Amjadi-Moheb,Gholam Ali Godazandeh,Shahryar Shafaei,Maryam Pilehchian Langroudi,Ali Akbar SamadaniHaleh Akhavan-Niaki, CTNNBIP1 downregulation is associated with tumor grade and viral infections in gastric adenocarcinoma. J Cell Physiol. 2018.

148.

Ghadami E, Nikbakhsh N, Fattahi S, Monfared MK, Ranaee M, Taheri H, et al. Epigenetic alterations of CYLD promoter modulate its expression in gastric adenocarcinoma: a footprint of infections. J Cell Physiol. 2018. https://doi.org/10.1002/jcp.27220.

149.

Samadani AA, Nikbakhsh N, Taheri H, Shafaee S, Fattahi S, Langroudi MP, et al. cdx1/2 and klf5 expression and epigenetic modulation of sonic hedgehog signaling in gastric adenocarcinoma. Pathol Oncol Res. 2019. https://doi.org/10.1007/s12253-019-00594-4.

150.

Fattahi S, Nikbakhsh N, Taheri H, Ghadami E, Kosari-Monfared M, Amirbozorgi G, et al. Prevalence of multiple infections and the risk of gastric adenocarcinoma development at earlier age. Diagn Microbiol Infect Dis. 2018;04(015). https://doi.org/10.1016/j.diagmicrobio.2018.04.015.

151.

Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. Cell Host Microbe. 2014;15:317–28.CrossRefPubMedPubMedCentral

152.

Garrett WS. Cancer and the microbiota. Science. 2015;348:80–6.CrossRefPubMedPubMedCentral

153.

Peuker K, Muff S, Wang J, et al. Epithelial calcineurin controls microbiota-dependent intestinal tumor development. Nat Med. 2016;22:506–15.CrossRefPubMedPubMedCentral

154.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. https://doi.org/10.3322/caac.21332.CrossRefPubMed

155.

Wallington M, Saxon EB, Bomb M, Smittenaar R, Wickenden M, McPhail S, et al. 30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study. Lancet Oncol. 2016;17(9):1203–16. https://doi.org/10.1016/S1470-2045(16)30383-7.CrossRefPubMedPubMedCentral

156.

Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine. N Engl J Med. 2012;366(6):489–91. https://doi.org/10.1056/NEJMp1114866.CrossRefPubMed

157.

Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum Pretium—the just price. J Clin Oncol. 2013;31(28):3600–4. https://doi.org/10.1200/JCO.2013.49.1845.CrossRefPubMedPubMedCentral

158.

Weber JS, Dummer R, de Pril V, Lebbé C, Hodi FS. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab. Cancer. 2013;119(9):1675–82. https://doi.org/10.1002/cncr.27969.CrossRefPubMed

159.

Welsh SJ, Rizos H, Scolyer RA, Long GV. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: where to next? Eur J Cancer. 2016;62:76–85. https://doi.org/10.1016/j.ejca.2016.04.005.CrossRefPubMed

160.

Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold G, et al. The gut microbiota and host health: a new clinical frontier. Gut. 2016;65(2):330–9. https://doi.org/10.1136/gutjnl-2015-309990.CrossRefPubMed

161.

Samet A, Śledzińska A, Krawczyk B, Hellmann A, Nowicki S, Kur J, et al. Leukemia and risk of recurrent Escherichia coli bacteremia: genotyping implicates E. coli translocation from the colon to the bloodstream. Eur J Clin Microbiol Infect Dis. 2013;32(11):1393–400. https://doi.org/10.1007/s10096-013-1886-9.CrossRefPubMedPubMedCentral

162.

Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51–72. https://doi.org/10.1146/annurev-immunol-032712-100008.CrossRefPubMed

163.

Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 2010;71(3):768–78. https://doi.org/10.1158/0008-5472.CrossRefPubMed

164.

Viaud S, Flament C, Zoubir M, Pautier P, Le Cesne A, Ribrag V, et al. Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res. 2011;1;71(3):661–5. https://doi.org/10.1158/0008-5472.CAN-10-1259.CrossRef

165.

LoGuidice A, Wallace BD, Bendel L, Redinbo MR, Boelsterli UA. Pharmacologic targeting of bacterial β-glucuronidase alleviates nonsteroidal anti-inflammatory drug-induced enteropathy in mice. J Pharmacol Exp Ther. 2012;341(2):447–54. https://doi.org/10.1124/jpet.111.191122.CrossRefPubMedPubMedCentral

166.

Saitta KS, Zhang C, Lee KK, Fujimoto K, Redinbo MR, Boelsterli UA. Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics. Xenobiotica. 2014;44(1):28–35. https://doi.org/10.3109/00498254.2013.811314.CrossRefPubMed

167.

Le Magnen C, Dutta A, Abate-Shen C. Optimizing mouse models for precision cancer prevention. Nat Rev Cancer. 2016;16(3):187–96. https://doi.org/10.1038/nrc.2016.1.CrossRefPubMedPubMedCentral

168.

Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol. 2003;163(5):2113–26. https://doi.org/10.1016/S0002-9440(10)63568-7.CrossRefPubMedPubMedCentral

169.

Dadachova E, Nguyen A, Lin EY, Gnatovskiy L, Lu P, Pollard JW. Treatment with rhenium-188-perrhenate and iodine-131 of NIS-expressing mammary cancer in a mouse model remarkably inhibited tumor growth. Nucl Med Biol. 2005;32(7):695–700. https://doi.org/10.1016/j.nucmedbio.2005.05.007.CrossRefPubMed

170.

Iyengar P, Espina V, Williams TW, Lin Y, Berry D, Jelicks LA, et al. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest. 2005;115(5):1163. https://doi.org/10.1172/JCI23424.CrossRefPubMedPubMedCentral

171.

Lin EY, Li J-f, Bricard G, Wang W, Deng Y, Sellers R, et al. Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. Mol Oncol. 2007;1(3):288–302. https://doi.org/10.1016/j.molonc.2007.10.003.CrossRefPubMedPubMedCentral

172.

Lin EY, Li J-F, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 2006;66(23):11238–46. https://doi.org/10.1158/0008-5472.CAN-06-1278.CrossRefPubMed

173.

Moadel RM, Nguyen AV, Lin EY, Lu P, Mani J, Blaufox MD, et al. Positron emission tomography agent 2-deoxy-2-[18F] fluoro-D-glucose has a therapeutic potential in breast cancer. Breast Cancer Res. 2003;5(6):R199. https://doi.org/10.1186/bcr643.CrossRefPubMedPubMedCentral

174.

Lin EY, Pollard JW. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 2007;67(11):5064–6. https://doi.org/10.1158/0008-5472.CAN-07-0912.CrossRefPubMed

175.

Wyckoff JB, Wang Y, Lin EY, Li J-f, Goswami S, Stanley ER, et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007;67(6):2649–56. https://doi.org/10.1158/0008-5472.CAN-06-1823.CrossRefPubMed

176.

Esbona K, Inman D, Saha S, Jeffery J, Schedin P, Wilke L, et al. COX-2 modulates mammary tumor pro77. Lin XB, Farhangfar A, Valcheva R, Sawyer MB, Dieleman L, Schieber A, et al. The role of intestinal microbiota in development of irinotecan toxicity and in toxicity reduction through dietary fibres in rats. PLoS One. 2014;9(1):e83644. https://doi.org/10.1371/journal.pone.0083644.CrossRef

177.

Lin XB, Farhangfar A, Valcheva R, Sawyer MB, Dieleman L, Schieber A, et al. The role of intestinal microbiota in development of irinotecan toxicity and in toxicity reduction through dietary fibres in rats. PLoS One. 2014;9(1):e83644. https://doi.org/10.1371/journal.pone.0083644.CrossRefPubMedPubMedCentral

178.

Villa A, Sonis ST. Mucositis: pathobiology and management. Curr Opin Oncol. 2015;27(3):159–64. https://doi.org/10.1097/CCO.0000000000000180.CrossRefPubMed

179.

Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 1994;54(14):3723–5.PubMed

180.

Voorde JV, Sabuncuoğlu S, Noppen S, Hofer A, Ranjbarian F, Fieuws S, et al. Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine. J Biol Chem. 2014;289(19):13054–65. https://doi.org/10.1074/jbc.M114.558924.CrossRef

181.

Montassier E, Batard E, Massart S, Gastinne T, Carton T, Caillon J, et al. 16S rRNA gene pyrosequencing reveals shift in patient faecal microbiota during high-dose chemotherapy as conditioning regimen for bone marrow transplantation. Microb Ecol. 2014;67(3):690–9. https://doi.org/10.1007/s00248-013-0355-4.CrossRefPubMed

182.

van Vliet MJ, Tissing WJ, Dun CA, Meessen NE, Kamps WA, de Bont ES, et al. Chemotherapy treatment in pediatric patients with acute myeloid leukemia receiving antimicrobial prophylaxis leads to a relative increase of colonization with potentially pathogenic bacteria in the gut. Clin Infect Dis. 2009;49(2):262–70. https://doi.org/10.1086/599346.CrossRefPubMed

183.

Montassier E, Gastinne T, Vangay P, Al-Ghalith G, Bruley des Varannes S, Massart S, et al. Chemotherapy-driven dysbiosis in the intestinal microbiome. Aliment Pharmacol Ther. 2015;42(5):515–28. https://doi.org/10.1111/apt.13302.CrossRefPubMed

Titel: Gut Microbiota as a Positive Potential Therapeutic Factor in Carcinogenesis: an Overview of Microbiota-Targeted Therapy
Publikationsdatum: 26.04.2019
Erschienen in: Journal of Gastrointestinal Cancer / Ausgabe 2/2020
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-019-00237-6

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Gut Microbiota as a Positive Potential Therapeutic Factor in Carcinogenesis: an Overview of Microbiota-Targeted Therapy

Abstract

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Inhibitory Traits of Dendrosome Curcumin (DNC) on Breast Cancer Compared to Curcumin Single Compound

Oxaliplatin-Induced Multiple Focal Nodular Hyperplasia Masquerading as Colorectal Liver Metastasis—Case Report and Review of Literature

Primary Leiomyosarcoma of the Pancreas: a Comprehensive Analytical Review

Primary Multifocal Hepatic PEComa: A Rarely Encountered Diagnostic Dilemma

Genetic Changes of P53 and Kras in Gallbladder Carcinoma in Kumaon Region of Uttarakhand

Comparison Between Multidetector CT and High–Field 3T MR Imaging in Diagnostic and Tumour Extension Evaluation of Patients with Cholangiocarcinoma

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie